Autoimmune gastritis has no cure, but treatment focuses on replacing the nutrients your stomach can no longer absorb, managing digestive symptoms, and monitoring for complications. Because the immune system gradually destroys the acid-producing cells in your stomach lining, the main problems are vitamin B12 deficiency, iron deficiency, and low stomach acid. Each of these requires its own approach.
Lifelong Vitamin B12 Replacement
The most critical part of treatment is replacing vitamin B12. Your stomach’s acid-producing cells also make a protein called intrinsic factor, which is essential for absorbing B12 from food. As autoimmune gastritis destroys these cells, B12 absorption drops dramatically, eventually leading to pernicious anemia if left untreated. The UK’s National Institute for Health and Care Excellence recommends lifelong B12 replacement for anyone whose deficiency is caused by autoimmune gastritis.
Traditionally, this meant regular intramuscular injections, since the whole problem is that your gut can’t absorb B12 normally. But clinical trials have shown that high-dose oral B12 (1,000 micrograms daily) can work surprisingly well even in pernicious anemia. In one randomized trial, patients taking oral B12 actually had higher blood levels at two and four months than those getting injections. A small amount of B12 is absorbed through passive diffusion in the intestine, bypassing the need for intrinsic factor entirely, but only when the dose is high enough.
Both routes produced similar improvements in neurological symptoms like numbness, balance problems, and memory issues. If you start on oral B12 and your symptoms don’t improve or get worse, your doctor may switch you to injections or increase their frequency. The key point is that some form of B12 replacement is non-negotiable and permanent. Stopping it will lead to deficiency again.
Treating Iron Deficiency
Iron deficiency is common in autoimmune gastritis and often shows up before B12 deficiency does. About 27% of patients with unexplained iron deficiency anemia in one study turned out to have autoimmune atrophic gastritis. The challenge is that low stomach acid impairs iron absorption, making standard oral iron supplements ineffective for many people. Roughly 71% of autoimmune gastritis patients with iron deficiency anemia don’t respond to oral iron therapy.
If oral iron isn’t raising your levels after a reasonable trial, intravenous iron infusions are the next step. These bypass the gut entirely and can restore iron stores more reliably. Vitamin C taken alongside meals may also help, as it enhances iron absorption even in a low-acid environment. Some researchers have suggested that restoring stomach acidity (discussed below) could improve oral iron uptake, though this hasn’t been proven in large trials yet.
Addressing Low Stomach Acid
One of the most overlooked aspects of autoimmune gastritis is the loss of stomach acid itself. Without adequate acid, you may experience bloating, early fullness, nausea, and poor digestion of protein. This is the opposite of the typical “too much acid” problem, and it’s worth noting that proton pump inhibitors, which suppress acid, are not appropriate here. Autoimmune gastritis is a condition that may benefit from acid supplementation, not acid suppression.
Betaine hydrochloride is an over-the-counter supplement that temporarily restores acidity when taken with meals. Experts in autoimmune gastritis recommend trying it to relieve the digestive symptoms caused by low acid. It’s a short-acting acidifying agent available in capsule form, often combined with pepsin, though your stomach likely still produces enough of its own protein-digesting enzymes that the added pepsin may not be necessary. Clinical trials specifically in autoimmune gastritis patients are still lacking, but early evidence suggests it’s well tolerated and may meaningfully improve symptoms.
The H. pylori Question
If you also have a Helicobacter pylori infection, the relationship with autoimmune gastritis is complicated. In some early-stage cases, eradicating H. pylori has led to improvement, with decreases in certain antibody levels and gastrin. But in other cases, clearing the infection has actually unmasked or accelerated autoimmune gastritis. There are documented cases where atrophic changes in the stomach progressed rapidly after H. pylori eradication, likely because the infection had been suppressing the autoimmune process.
This doesn’t mean you should avoid treating H. pylori. The bacteria carry their own serious risks, including ulcers and cancer. But if you have both conditions, your doctor should monitor your stomach closely after eradication therapy, watching for signs that the autoimmune component is progressing. For patients with iron deficiency anemia, eradicating H. pylori alongside continued oral iron did produce significant improvements in hemoglobin levels within three to six months in one study.
Screening for Related Autoimmune Conditions
Autoimmune gastritis rarely travels alone. In a study of 320 patients, over 53% had at least one other autoimmune condition. The most common companion is autoimmune thyroid disease, particularly Hashimoto’s thyroiditis, found in about 36% of autoimmune gastritis patients. The overlap runs both ways: roughly 40% of people with Hashimoto’s thyroiditis also have autoimmune gastritis.
Other associated conditions include type 1 diabetes, vitiligo, Addison’s disease, and certain skin conditions like erosive oral lichen planus. If you’ve been diagnosed with autoimmune gastritis, it’s worth being screened for thyroid disease and other autoimmune disorders. Conversely, if you already have an autoimmune condition, periodic checks of your B12 levels every three to five years can help catch autoimmune gastritis early.
Endoscopic Surveillance for Cancer Risk
Autoimmune gastritis increases the risk of two types of stomach growths: gastric adenocarcinoma and a type of neuroendocrine tumor. Regular upper endoscopy is the primary tool for catching these early. The American Gastroenterological Association recommends considering surveillance endoscopy every three years for people with advanced atrophic gastritis, while European guidelines suggest every three to five years for autoimmune gastritis specifically.
If you’ve already been diagnosed with pernicious anemia (the late stage of B12 deficiency from autoimmune gastritis), the risk of gastric cancer appears highest in the first year after diagnosis. The American Society of Gastrointestinal Endoscopy recommends getting an upper endoscopy within six months of a pernicious anemia diagnosis. If small neuroendocrine tumors are found and removed during endoscopy, follow-up surveillance every one to two years is typically recommended depending on tumor burden.
The exact surveillance schedule should be tailored to your individual risk. Factors like the extent of atrophy, family history, and whether neuroendocrine tumors have been found all influence how often you need scoping.
Monitoring Disease Progression
You might wonder whether tracking antibody levels over time is useful. Parietal cell antibodies, the immune markers that define this disease, tend to fluctuate unpredictably. They’re often highest in the early stages and gradually decline as more parietal cells are destroyed, sometimes becoming undetectable in late-stage disease. This paradoxical drop doesn’t mean improvement; it means fewer target cells remain.
Research consistently shows that antibody levels alone don’t reliably reflect what’s happening in your stomach. In one follow-up study, antibody levels remained essentially stable over seven years regardless of disease stage. A more complete picture comes from combining antibody testing with functional markers like pepsinogen I and II levels and gastrin, which reflect how well your stomach is actually working. Pepsinogen levels drop as acid-producing tissue is lost, while gastrin levels rise as the body tries to stimulate acid production that can no longer happen. Together, these blood tests can help your doctor decide when endoscopy is warranted without relying on scope alone.
What Immunosuppressive Therapy Can and Cannot Do
Because autoimmune gastritis is driven by the immune system, it’s natural to ask whether suppressing the immune response could slow or stop the damage. In practice, this approach has very limited evidence. In one documented case, corticosteroids provided moderate symptom relief and partial healing of gastric ulcers, but symptoms returned every time the dose was tapered. Sequential trials of several different immunosuppressive and biologic medications over many months failed to produce lasting improvement.
As of now, management of autoimmune gastritis centers on nutritional replacement and cancer surveillance rather than altering the underlying immune attack. This may change as research evolves, but currently there is no established immunosuppressive regimen for this condition.